Elevation Point Wealth Partners LLC Acquires 11,696 Shares of Cencora, Inc. $COR

Key Points

• Elevation Point Wealth Partners increased its Cencora stake by 397.1% in the first quarter, buying 11,696 additional shares and bringing its total holding to 14,641 shares worth about $4.6 million.
• Wall Street sentiment on Cencora remains constructive overall, with 11 analysts rating it a Buy and four a Hold, giving the stock a consensus Moderate Buy and an average price target of $367.75.
• Cencora’s recent earnings missed estimates, but the company still grew revenue 3.9% year over year and authorized a $2 billion share buyback while continuing its quarterly dividend of $0.60 per share.

Elevation Point Wealth Partners LLC lifted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 397.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,641 shares of the company's stock after buying an additional 11,696 shares during the period. Elevation Point Wealth Partners LLC's holdings in Cencora were worth $4,599,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Kemnay Advisory Services Inc. purchased a new stake in shares of Cencora in the fourth quarter valued at $25,000. Oakworth Capital Inc. bought a new position in Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC purchased a new stake in Cencora in the fourth quarter worth $27,000. Archer Investment Corp increased its stake in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company's stock worth $28,000 after purchasing an additional 47 shares during the period. Finally, Motiv8 Investments LLC bought a new stake in shares of Cencora during the fourth quarter worth $29,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on COR shares. Leerink Partners restated an "outperform" rating on shares of Cencora in a report on Tuesday, March 17th. UBS Group lifted their price objective on shares of Cencora from $410.00 to $412.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Citigroup dropped their target price on shares of Cencora from $405.00 to $355.00 and set a "buy" rating on the stock in a research note on Thursday, May 7th. Weiss Ratings lowered shares of Cencora from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday. Finally, Evercore set a $360.00 price target on shares of Cencora in a research note on Wednesday, April 8th. Eleven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $367.75.

Insider Activity at Cencora

In related news, Director Lauren M. Tyler acquired 550 shares of the firm's stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the purchase, the director directly owned 4,359 shares of the company's stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.38% of the company's stock.

Cencora Trading Down 0.0%

NYSE:COR opened at $296.43 on Friday. The firm has a 50-day simple moving average of $277.91 and a 200-day simple moving average of $320.37. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The firm has a market cap of $57.67 billion, a P/E ratio of 22.73, a P/E/G ratio of 1.65 and a beta of 0.58. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora's revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora's dividend payout ratio (DPR) is currently 18.40%.

Cencora announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.

About Cencora

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.